Whitehawk Therapeutics (WHWK) Operating Expenses (2013 - 2026)

Whitehawk Therapeutics (WHWK) has 14 years of Operating Expenses data on file, last reported at $23.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $23.5 million, up 5.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.7 million (up 34.93% YoY), and the FY2025 annual result was $121.5 million, up 30.08% from the prior year.
• Operating Expenses slipped to $23.5 million in Q1 2026 per WHWK's latest filing, from $24.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $54.7 million in Q2 2025 and troughed at $16.1 million in Q1 2022.
• A 5-year average of $24.3 million and a median of $22.7 million in 2023 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 462.5% in 2022 and fell as far as 77.92% in 2022.
• A 5-year view of Operating Expenses shows it stood at $20.7 million in 2022, then rose by 16.14% to $24.0 million in 2023, then advanced by 8.94% to $26.2 million in 2024, then declined by 4.97% to $24.9 million in 2025, then declined by 5.48% to $23.5 million in 2026.
• Business Quant data shows WHWK's Operating Expenses at $23.5 million in Q1 2026, $24.9 million in Q4 2025, and $19.5 million in Q3 2025.